Skip to content

Hemodialysis and Erythrocyte Fatty-Acid Status: a Lipidomics Study

Hemodialysis and Erythrocyte Fatty-Acid Status: a Lipidomics Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03857984
Enrollment
30
Registered
2019-02-28
Start date
2018-05-01
Completion date
2022-02-01
Last updated
2022-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erythrocytes, Fatty Acid Metabolism, Hemodialysis, Lipidomics

Brief summary

Hypotension with potentially serious consequences for organ perfusion is a common complication in extracorporeal procedures such as hemodialysis / hemofiltration. The exact reasons for this are still insufficiently clarified. Probably periinterventional vasorelaxant released substances play a crucial role in these procedures. These substances could be due to contact of blood cells with the Membrane in the dialyzer / hemofilter arise. In this project the hypothesis will be checked, if EETs / DHETs are released by Erythrocytes during hemodialysis and thus act as potential candidate products for the result of hypotonic phases in the Dialysis. We will determine differences in RBC fatty acids profiling in hemodialysis patients before and after dialysis intervention. Furthermore a matched control group of healthy individuals will be profiled. RBC fatty acids profiling will be achieved by using targeted HPLC-MS mass spectrometry. It is believed that during hemodialysis / HLM / CVVH there is an increase in EETs / DHETs in the serum and in the erythrocytes. It is believed that shear forces play an important role in the release of erythrocyte EETs / DHETs.

Detailed description

Differences in Erythrocyte Fatty-Acid Status Profiling in: * before and after hemodialysis intervention * in hemodialysis patients and healthy individuals Venous blood will be collected from each subject in the sitting position

Interventions

OTHERBlood sampling

blood sample before and after a single HD

Sponsors

Benjamin Gollasch
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

for hemodialysis patients: * Patients who have a history of renal failure and undergo hemodialysis / hemofiltration * Age over 18 years * Ability to consent * There is a written consent of the study participant

Exclusion criteria

for healthy control group: * chronic illness requiring any medication * pregnancy * limitations regarding functioning in the hypoxic chamber * inability to follow simple instructions relevant or severe abnormalities in medical history, physical examination

Design outcomes

Primary

MeasureTime frameDescription
Coefficient of variation of relative quantities of erythrocyte fatty-acid parameters related to its dynamic during Hemodialysis, using LC-MS / MS.4-5 MonthsEETs / DHETs will be analyzed in the erythrocytes and serum of the recovered blood samples. The determination will made in cooperation with a Berliner Biotech company. This involves liquid chromatography with MS coupling (LC-MS / MS) used. The data analysis is carried out by means of suitable statistical methods to perform erythrocyte fatty-acid status profiling.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026